Register Now

Event Schedule

Have a look at Schedule

Day 1: Innovations in Early Drug Discovery & Technologies

8:00

Bright Start

Registration + Coffee With Impactful Investors

8:50

Chair Welcome Address
World BI 2025
Soroush Safaei

Senior Principal Scientist, Sanofi

9:00

Keynote Session

Neuroscience Drug Discovery – Where is the Innovative Biology Coming From and What Do We Miss?

World BI 2025
Johan Luthman

EVP & Head of R&D, Lundbeck

Target Identification & Hit Discovery

9:20

Talk 1

Human-Centric Target Discovery Leveraging In Vitro & In Silico Models

World BI 2025
Jakob E. Larsen

Target Discovery Director, Novo Nordisk

9:40

Partner Slot 1

Smarter Together? Advancing Predictive Data Analytics Tools in Target ID & Validation

World BI 2025
Joelle Gola

Senior Application Scientist, CAS - a division of the American Chemical Society

10:00

Featured Presentation

Harnessing Genetic Resilience: A New Paradigm for Target Discovery with GenMor-AI

World BI 2025
David Bearss

CEO, Halia Therapeutics

10:20

Coffee Break & Networking Session

AI & Automation in Drug Discovery-I

11:10

Talk 2

Accelerating and Scaling Machine Learning for Enhanced Integration and Decision-Making in Roche's Drug Discovery Pipeline

World BI 2025
Le (Muller) Mu

MLOps Product Owner, Roche

11:30

Partner Slot 2

Advancing Cancer Biomarkers and Antiviral Research

World BI 2025
Dr Joseph Lackey

Technical Manager, LGC Standards

11:55

Talk 3

GenAI Meets RWD: Building a Multi-Agent GenAI Platform for RWD/RWE & Insight

World BI 2025
Abhishek (ABC) Choudhary

Principal Data Engineer, Bayer

12:15

Talk 4

What Progress Have We Made in AI-Augmented Drug Discovery?

World BI 2025
Aisyah Sjöholm

Associate Director, Insilico Medicine

12:35

Lunch Break & One-on-One Meetings

Strategies for Addressing ‘Undruggable’ Targets

13:35

Keynote Presentation

Fast-Tracking Drug Discovery: Innovative Modalities and Strategies for Unlocking High-Value Targets

World BI 2025
Stefan Geschwindner

Director Biophysics, AstraZeneca

14:05

Partner Slot 3

An Integrated Screening Strategy to Evaluate the Therapeutic Potential of Both Peptide and Non-peptide GLP-1 RAs in Preclinical Metabolic Models

World BI 2025
Sumit Chaudhary

Director, In Vivo Pharmacology, Sai Life Sciences

14:25

Talk 5

QUANTROseq®, a Transcriptomic Based Drug Discovery Platform for Transcription Factors and Cell Signaling Regulators

World BI 2025
Arianna Sabò

Head of Research, Quantro Therapeutics

14:45

Partner Slot 4

Digital Chemistry Offering at Merck, Covering the Workflow from Drug Discovery to Synthesis to Sourcing of Chemical Libraries

World BI 2025
Angelo Lanzilotto

Solution Sales Specialist - Digital Chemistry, Merck KGaA

14:55

Pitch Deck Session for Startups

15:05

Interactive Panel

Turning the Tide on Undruggable Targets: Emerging Modalities

Panellists

Worldbi Speaker
Heena Khatter

Principal Scientist, Roche

Worldbi Speaker
Pascal Benderitter

Head of Medicinal Chemistry, QUANTRO Therapeutics GmbH

Worldbi Speaker
Stefan Geschwindner

Director Biophysics, AstraZeneca

15:35

Coffee Break & Networking Session

Innovations in Medicinal Chemistry

16:25

Keynote Presentation

ATM Kinase Inhibitor Lartesertib: A Pioneering Application of Atropisomerism in Drug Design

World BI 2025
Dr. Thomas Fuchss

Director Medicinal Chemistry, Merck

16:45

Partner Slot 5

From Edits To Insights - How Custom CRISPR Cell Models are Rewriting Drug Discovery

World BI 2025
Zofia Świątczak

Head of Sales - Europe, EditCo

16:55

Talk 6

Novel Chemical Modalities: Expanding Drug Space Beyond Traditional Molecules

World BI 2025
Sonia Novo

Principal Scientist, UCB

17:15

Talk 7

Best-in-Class Oligonucleotide Therapeutics to Expand the Universe of Druggable Targets

World BI 2025
Frank Jaschinski

CSO, Secarna Pharmaceuticals

17:35

Closing Remarks
World BI 2025
Soroush Safaei

Senior Principal Scientist, Sanofi

17:40

Happy Hour Session

Day 2: Advancing Drug Discovery Through Biologics and New Therapeutic Modalities

8:00

Bright Start

Registration + Coffee With Impactful Investors

8:50

Chair Welcome Address
World BI 2025
Soroush Safaei

Senior Principal Scientist, Sanofi

9:00

Keynote Presentation

Hot-Melt Extrusion (HME): A Cost-effective Approach to Enhancing Bioavailability

World BI 2025
Dr. Devendra Ridhurkar

Founder and CEO, RidNova

AI & Automation in Drug Discovery-II

9:20

Talk 1

Transforming Drug Discovery: Generative Models and Electrostatic Complementarity

World BI 2025
Rinaldo Montalvão

Director AI, Gain Therapeutics

9:40

Featured Talk

Predicting Drug Efficacy in Virtual Patients

World BI 2025
Philippe Moingeon

Adj. Professor, AI in Health, Université Paris-Saclay

10:00

Talk 2

Identification and Validation of Pharmacological Non-Coding Targets

World BI 2025
Alessandro Bonetti

Director Neuroscience, AstraZeneca

10:20

Business Card Exchange: Coffee Break

Translational Medicine & Personalized Therapeutics

11:10

Keynote Presentation

Precision Medicine 2.0: Harnessing the Oncobiome for Personalized Cancer Therapy

World BI 2025
Rafik Fellague-Chebra

Global Medical Director, Novartis Oncology

11:40

Talk 3

How to Predict and Prevent Pre-eclampsia by Tackling the Root Cause of the Disease

World BI 2025
Prof. Asif Ahmed

CEO, Mirzyme

12:00

Case Study

From Vision to Impact: AOP Health's 30-Year Journey in Rare Diseases and the Road Ahead

World BI 2025
Carmen Visus

Sr. Director, R&D Ops, AOP Health

12:20

Pitch Deck Session for Startups

12:30

Lead Generation Luncheon

13:30

Startup Investor Panel

What Investors Want in Early-Stage Biotech

Panellists

Worldbi Speaker
Jason Mellad

CEO, Start Codon

Worldbi Speaker
Gemma Guinart Mola

Principal, Invivo Partners

Worldbi Speaker
Thomas Harth

Partner, Ysios Capital

Worldbi Speaker
Daniel Rooke

Co-Founder and Strategic Advisor, Start Codon

14:10

Coffee Break & Networking Session

Advancements in Biologics and Therapeutic Antibodies

15:00

Featured Talk

New Trends in Complex Cell Models

World BI 2025
David Moreno Delgado

Director, UCB

15:20

Talk 4

Pioneering a First in Class Anti-Necrotic™

World BI 2025
Dr. Carina Kern

CEO & Founder, LinkGevity

15:40

Talk 5

JJP-1008: Anti-CD270 Antibody Checkpoint Inhibitor for Cancer Treatment: Swing Around Patient’s CD270 Immunosuppressive Disadvantage

World BI 2025
Tomasz Sitar

Head of CMC, JJP Biologics

16:00

Final Remarks
World BI 2025
Soroush Safaei

Senior Principal Scientist, Sanofi

16:20

End of Day 2